The myriad presentations of peripartum cardiomyopathy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242082Keywords:
Echocardiography, Systolic dysfuction, Cardiogenic shock, Digoxin, PPCM, Heart disease in pregnancy, Beta-blockersAbstract
Peripartum cardiomyopathy (PPCM) is an idiopathic, non-ischemic systolic type of heart failure which can present anytime from the last month of pregnancy till the end of 5th month post-partum. The incidence of PPCM in the Indian population is 1:1340 with 60% of the cases occurring post-partum. PPCM has a mortality rate of 11.7% with unpredictable sequelae ranging from worsening heart failure, cardiogenic shock, development of arrythmias to complete recovery and recurrence in subsequent pregnancies. With an idiopathic aetiology with multiple theories, PPCM remains a diagnosis of exclusion, demanding a high index of suspicion and surveillance in pregnant women. The management involves a multidisciplinary approach involving the obstetrician, cardiologist and at times the anaesthesiologist and includes various drugs like beta- blockers, diuretics, digoxin, bromocriptine. In severe cases, maternal circulatory support may also be needed. We present three cases of PPCM diagnosed in the antepartum, intrapartum and immediate post-partum periods respectively. Out of 3 patients, one delivered vaginally and two underwent emergency caesarean sections. All of patients went home post-delivery with good outcomes and were doing well after 4 weeks of delivery.
Metrics
References
Bauersachs J, Konig T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21:827-43.
Pearson GO, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283(9):1183-8.
Sliwa K, Hilfiker-Kleiner D, Petrie MC, Alexandre M, Burkert P, Eckhart B, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12:767-78.
Agarwal R, Baid R, Sinha DP. Peripartum Cardiomyopathy in Indian Population: A Pooled Analysis. J Clin Preventive Cardiol. 2021;10(2):54-7.
Davis M, Arany Z, McNamara D. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(2):207-21.
Hoevelmann J, Viljoen CA, Manning K, Baard J, Hahnle L, Ntsekhe M, et al. The prognostic significance of the 12-lead ECG in peripartum cardiomyopathy. Int J Cardiol. 2019;276:177-84.
Wong CM, Hawkins NM, Jhund PS, Michael RM, Scott DS, Christopher BG, et al. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013;62(20):1845-54.
Bozkurt B, Colvin M, Cook J, Leslie TC, Anita D, Gregg CF, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-646.
Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-8.
Van Spaendonck-Zwarts KY, Posafalvi A, Van den Berg MP, Hilfiker-Kleiner D, Bollen IA, Sliwa K, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014;35(32):2165-73.
Ahmed A, Spinty S, Murday V, Longman C, Khand A. A de-novo deletion of dystrophin provoking severe ‘peri-partum cardiomyopathy’: the importance of genetic testing in peripartum cardiomyopathy to uncover female carriers. Int J Cardiol. 2016;203:1084-5.
Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Christian V, Andrew JSC, Maria GCL, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18(9):1096-105.
Biteker M, Duran NE, Kaya H, Sabahattin G, Halil ÎT, Tayyar G, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol. 2011;100(7):571-7.
Gevaert S, Van Belleghem Y, Bouchez S, Ingrid H, Filip DS, Yasmina DB, et al. Acute and critically ill peripartum cardiomyopathy and ’bridge to’ therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation and continuous flow left ventricular assist devices. Crit Care. 2011;15(2):R93.
Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344(21):1567-71.
Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36(27):1728-34.
Downloads
Published
How to Cite
Issue
Section
